NCT02567435 2026-03-17
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
69 trialsNCT07194044 2026-03-16
METTSEO
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT05440786 2026-03-12
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Eli Lilly and Company
Phase 2 Active not recruiting
NCT07466316 2026-03-12
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Children's Oncology Group
Phase 3 Not yet recruiting
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT06541262 2026-03-02
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Milton S. Hershey Medical Center
Phase 1/2 Recruiting
NCT04619056 2026-02-19
First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma
CEBIOTEX
Phase 1 Completed
NCT05400603 2025-12-26
Aflac-NBL-2002
Emory University
Phase 1 Recruiting
NCT01858168 2025-12-19
Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma
Massachusetts General Hospital
Phase 1 Completed
NCT01871766 2025-12-17
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT04067115 2025-12-17
U01CA236220
Sarcoma Alliance for Research through Collaboration
Phase 1/2 Completed
NCT02192359 2025-11-14
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Phase 1 Active not recruiting
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT04095221 2025-02-20
A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT03709680 2025-01-14
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
Phase 2 Active not recruiting
NCT03678883 2024-11-07
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT01837862 2024-07-05
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Northwell Health
Phase 1/2 Completed
NCT04625907 2024-05-23
FaR-RMS
University of Birmingham
Phase 1/2 Recruiting
NCT02085148 2024-04-22
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Bayer
Phase 1 Completed
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT02095132 2023-09-26
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT03495921 2023-04-26
VITA
Gradalis, Inc.
Phase 3 Terminated
NCT00354835 2023-01-31
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
Children's Oncology Group
Phase 3 Completed
NCT02511132 2022-12-22
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Gradalis, Inc.
Phase 2 Completed
NCT02727387 2022-09-19
EW-2
Italian Sarcoma Group
Phase 2 Completed
NCT03245450 2022-06-28
Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT05042934 2022-02-10
Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT02044120 2021-01-12
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma
Sarcoma Alliance for Research through Collaboration
Phase 1 Completed
NCT03139331 2021-01-05
PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma
University of California, San Francisco
Phase 1 Completed
NCT00354744 2020-01-29
High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
Children's Oncology Group
Phase 3 Completed
NCT01355445 2019-09-18
VIT-0910
Centre Oscar Lambret
Phase 2 Completed
NCT03416517 2019-02-15
Anlotinib and Irinotecan for Ewing Sarcoma
Peking University People's Hospital
Phase 1/2 Unknown
NCT00671801 2018-11-13
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00433381 2018-09-17
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00960063 2018-08-27
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01086345 2018-07-03
Radiosurgery Plus Bevacizumab in Glioblastoma
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT02331251 2018-07-02
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Western Regional Medical Center
Phase 1/2 Terminated
NCT01313884 2017-11-24
Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
Stanford University
Phase 2 Terminated
NCT01055314 2017-08-29
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00654160 2017-05-25
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
Mayo Clinic
Phase 1 Completed
NCT00027612 2016-12-07
Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT00996346 2015-09-01
Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas
New Mexico Cancer Research Alliance
Phase 1 Terminated
NCT00003484 2015-04-23
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
Duke University
Phase 1 Completed
NCT01518413 2015-02-27
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Children's National Research Institute
Phase 1 Completed
NCT01380275 2014-09-25
Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.
National Cancer Center, Korea
Phase 2 Unknown
NCT00544778 2014-08-28
Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma
City of Hope Medical Center
Phase 2 Terminated
NCT00005951 2014-08-22
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
Duke University
Phase 1 Completed
NCT00352521 2014-07-22
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma
Duke University
Phase 2 Completed